UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 OR 15(d) of
                       The Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported) March 31, 2005


                               SWISS MEDICA, INC.
             (Exact name of registrant as specified in its charter)


          Delaware                   000-09489                    98-0355519
(State or other jurisdiction        (Commission                 (IRS Employer
       of incorporation)            File Number)             Identification No.)


          53 Yonge Street, 3rd Floor                             M5E 1J3
               Toronto, Ontario, Canada                        (Zip Code)
    (Address of principal executive offices)

        Registrant's telephone number, including area code (416) 868-0202

--------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))


<PAGE>


Item 1.01 Entry into a Material Definitive Agreement

      See the information set forth under "Item 2.01 Completion of Acquisition
or Disposition of Assets," which is incorporated by reference into this Item
1.01.

Item 2.01 Completion of Acquisition or Disposition of Assets

      On March 31, 2005, Swiss Medica, Inc., a Delaware corporation (the
"Company"), Anti-Depression BioHealth Solutions, Inc., a Florida corporation
("ADBSI") and UTEK Corporation, a Delaware corporation ("UTEK") entered into an
Agreement and Plan of Acquisition (the "Acquisition Agreement"). The acquisition
of ADBSI was completed pursuant to the terms of the Acquisition Agreement and
closed on March 31, 2005. All outstanding shares of common stock of ADBSI were
exchanged for 2,105,263 unregistered shares of Class A common stock of the
Company. As additional consideration pursuant to the terms of the Acquisition
Agreement, the Company paid UTEK, the sole shareholder of ADBSI, $96,673.00 in
cash. As result of the closing under the Acquisition Agreement, ADBSI became a
wholly-owned subsidiary of the Company.

      There are no material relationships between the Company or its affiliates
and any of the parties to the Acquisition Agreement, other than in respect of
the Acquisition Agreement.

      On March 31, 2005, in connection with the Acquisition Agreement, ADBSI
obtained a 48-month exclusive option to acquire an exclusive license to
Nutraceutical intellectual property and products developed or manufactured using
the Nutraceutical intellectual property from Back Bay pursuant to the terms of
the Option Agreement, subject to the rights of existing licenses to such
technology (the "Option Agreement"). ADBSI may exercise this option after
receipt of Back Bay Scientific, Inc.'s, a Delaware corporation ("Back Bay"),
notice of completion of the development of Nutraceutical intellectual property
or related products, or upon termination of an existing license agreement
relating to the Nutraceutical technology. The terms of a license agreement for
Nutraceutical intellectual property will entitle ADBSI to the same terms of the
Patent License Agreement dated March 31, 2005, between ADBSI and Back Bay
("Patent License Agreement"). Pursuant to the terms of the Option Agreement, if
Massachusetts Institute of Technology, or the patent assignor, requires an
upfront fee, this fee will be passed through to ADBSI and a portion of it will
be applied towards future royalty payments. If ADBSI does not exercise its
option after receipt of the notice, the Option Agreement terminates as to the
specific Nutraceutical intellectual property or product as described in such
notice. ADBSI's option continues during the 48-month term with respect to any
materially more valuable or materially more commercially viable Nutraceutical
intellectual property or products that may be developed. In consideration for
the Option, ADBSI agreed to pay Back Bay $60,000 in four equal payments of
$15,000. The first payment was made upon the effectiveness of the Option
Agreement, and the remaining three payments are due on the first, second and
third anniversary dates of the Option Agreement. ADBSI has already paid the
first $15,000 installment. ADBSI's ability to exercise the option pursuant to
the Option Agreement is subject to the ability to license the underlying
intellectual property from Massachusetts Institute of Technology.

      ADBSI's assets include an exclusive license to, among other things,
develop and market patented and proprietary PMS Escape product pursuant to the
Patent License Agreement. This royalty-bearing exclusive license gives ADBSI
rights to use, manufacture and distribute the PMS Escape product or any other
product developed from certain patent rights licensed to Back Bay in the United
States and Canada. This agreement also gives ADBSI the rights to use all
intellectual property related to PMS Escape, except the patent rights, in
connection with the marketing, sale and distribution of the product. Pursuant to
the terms of the agreement, ADBSI may market PMS Escape product under a
different name and sublicense its rights, subject to Back Bay's written consent.
Upon the execution of this agreement, ADBSI agrees to pay a one-time,
non-refundable fee of $125,000 to Back Bay and to prepay for Back Bay's finished
PMS Escape and packaging inventory. The $125,000 fee was paid on ADBSI's behalf
by UTEK. The Company in turn, paid UTEK $25,000 to cover a portion of such fee.
In exchange for the license, ADBSI must pay BBS a royalty equal to 5% of the net
sales of PMS Escape and other products covered under the License Agreement.
Pursuant to the terms of the Acquisition Agreement, ADBSI will provide to Back
Bay a business plan that outlines the development and commercialization of the
PMS Escape product. Under this agreement, if ADBSI does not meet the annual
minimum royalty payments after the first year, Back Bay has the right to convert
the license to a non-exclusive license. ADBSI has the right, but not the
obligation, to prosecute any actions concerning any claims of infringement. The
term of this agreement is five years, with automatic three-year renewal terms so
long as royalty payments have been paid to Back Bay pursuant to the agreement.
ADBSI has the right to terminate the Patent License Agreement for Back Bay's
uncured breach of the license or by providing prior written notice to Back Bay
at least six months prior to either the expiration of the term on March 31, 2010
or each three-year renewal term. Back Bay may terminate the agreement for
ADBSI's uncured breach of the agreement or upon prior written notice in the
event the license becomes non-exclusive or if ADBSI ceases to conduct its
business related to this agreement.


<PAGE>


      ADBSI also entered into a Consulting Agreement with Back Bay and its
principals Marc Tobin, Judith Wurtman, Ph.D. and Dr. Richard Wurtman on March
31, 2005. Pursuant to the terms of the Consulting Agreement, Mr. Tobin, Dr.
Judith Wurtman and Dr. Richard Wurtman will provide consulting services relating
to PMS Escape and other products to which ADBSI obtains rights under the Patent
License Agreement. The initial term of the Consulting Agreement expires on April
1, 2009 and automatically renews for additional one-year terms, unless the
Patent License Agreement is no longer in effect or either party elects not to
renew the Consulting Agreement at least 30 days prior to the expiration of the
initial or renewal term. Upon the execution of the Consulting Agreement, gave
Back Bay a 10% equity ownership in ADBSI, which, in turn, converted into 10% of
the equity ownership UTEK received from the Company upon consummation of the
Acquisition Agreement. In consideration for the Consulting Agreement, ADBSI
agreed to pay Back Bay $200,000 in four equal payments of $50,000. The first
payment was made upon the effectiveness of the Consulting Agreement, and the
remaining three payments are due on the first, second and third anniversary
dates of the Consulting Agreement.

      The Acquisition Agreement and Press Release are filed herewith and are
incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(a) The Company will file financial statements of the business acquired, and any
required pro forma financial information, by an amendment to this Current
Report, which will be filed no later than the date required by Item 9.01 of Form
8-K.


(c) Exhibits.

Exh. No. Description
-------  -----------
10.1.    Agreement and Plan of Acquisition, dated March 31, 2005, by and
         between the Company, Anti-Depression BioHealth Solutions, Inc. and UTEK
         Corporation.

99.1     Press Release issued April 5, 2005.



                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                               SWISS MEDICA, INC.
                                                  (Registrant)

Date: April 6, 2005
                                       /s/ Raghu Kilambi
                                       --------------------------------------
                                       Raghu Kilambi, Chief Executive Officer
{"company-data": {"conformed-name": "SWISS MEDICA INC", "cik": "0000318245", "assigned-sic": "2834", "irs-number": "980355519", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-09489", "film-number": "05737740"}, "business-address": {"street1": "53 YONGE STREET, 3RD FLOOR", "street2": "TORONTO", "city": "ONTARIO, CANADA", "state": "A1", "zip": "M5E 1J3", "phone": "416-657-4134"}, "mail-address": {"street1": "53 YONGE STREET, 3RD FLOOR", "street2": "TORONTO", "city": "ONTARIO, CANADA", "state": "A1", "zip": "M5E 1J3"}, "former-company": [{"former-conformed-name": "SWISS MEDIA INC", "date-changed": "20030702"}, {"former-conformed-name": "GLOBAL PATH INC", "date-changed": "20010814"}, {"former-conformed-name": "YOURNET INC/", "date-changed": "19991108"}]}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 OR 15(d) of
                       The Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported) March 31, 2005

                               SWISS MEDICA, INC.
             (Exact name of registrant as specified in its charter)

          Delaware                   000-09489                    98-0355519
(State or other jurisdiction        (Commission                 (IRS Employer
       of incorporation)            File Number)             Identification No.)

          53 Yonge Street, 3rd Floor                             M5E 1J3
               Toronto, Ontario, Canada                        (Zip Code)
    (Address of principal executive offices)

        Registrant's telephone number, including area code (416) 868-0202

--------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement

      See the information set forth under "Item 2.01 Completion of Acquisition
or Disposition of Assets," which is incorporated by reference into this Item
1.01.

Item 2.01 Completion of Acquisition or Disposition of Assets

      On March 31, 2005, Swiss Medica, Inc., a Delaware corporation (the
"Company"), Anti-Depression BioHealth Solutions, Inc., a Florida corporation
("ADBSI") and UTEK Corporation, a Delaware corporation ("UTEK") entered into an
Agreement and Plan of Acquisition (the "Acquisition Agreement"). The acquisition
of ADBSI was completed pursuant to the terms of the Acquisition Agreement and
closed on March 31, 2005. All outstanding shares of common stock of ADBSI were
exchanged for 2,105,263 unregistered shares of Class A common stock of the
Company. As additional consideration pursuant to the terms of the Acquisition
Agreement, the Company paid UTEK, the sole shareholder of ADBSI, $96,673.00 in
cash. As result of the closing under the Acquisition Agreement, ADBSI became a
wholly-owned subsidiary of the Company.

      There are no material relationships between the Company or its affiliates
and any of the parties to the Acquisition Agreement, other than in respect of
the Acquisition Agreement.

      On March 31, 2005, in connection with the Acquisition Agreement, ADBSI
obtained a 48-month exclusive option to acquire an exclusive license to
Nutraceutical intellectual property and products developed or manufactured using
the Nutraceutical intellectual property from Back Bay pursuant to the terms of
the Option Agreement, subject to the rights of existing licenses to such
technology (the "Option Agreement"). ADBSI may exercise this option after
receipt of Back Bay Scientific, Inc.'s, a Delaware corporation ("Back Bay"),
notice of completion of the development of Nutraceutical intellectual property
or related products, or upon termination of an existing license agreement
relating to the Nutraceutical technology. The terms of a license agreement for
Nutraceutical intellectual property will entitle ADBSI to the same terms of the
Patent License Agreement dated March 31, 2005, between ADBSI and Back Bay
("Patent License Agreement"). Pursuant to the terms of the Option Agreement, if
Massachusetts Institute of Technology, or the patent assignor, requires an
upfront fee, this fee will be passed through to ADBSI and a portion of it will
be applied towards future royalty payments. If ADBSI does not exercise its
option after receipt of the notice, the Option Agreement terminates as to the
specific Nutraceutical intellectual property or product as described in such
notice. ADBSI's option continues during the 48-month term with respect to any
materially more valuable or materially more commercially viable Nutraceutical
intellectual property or products that may be developed. In consideration for
the Option, ADBSI agreed to pay Back Bay $60,000 in four equal payments of
$15,000. The first payment was made upon the effectiveness of the Option
Agreement, and the remaining three payments are due on the first, second and
third anniversary dates of the Option Agreement. ADBSI has already paid the
first $15,000 installment. ADBSI's ability to exercise the option pursuant to
the Option Agreement is subject to the ability to license the underlying
intellectual property from Massachusetts Institute of Technology.

      ADBSI's assets include an exclusive license to, among other things,
develop and market patented and proprietary PMS Escape product pursuant to the
Patent License Agreement. This royalty-bearing exclusive license gives ADBSI
rights to use, manufacture and distribute the PMS Escape product or any other
product developed from certain patent rights licensed to Back Bay in the United
States and Canada. This agreement also gives ADBSI the rights to use all
intellectual property related to PMS Escape, except the patent rights, in
connection with the marketing, sale and distribution of the product. Pursuant to
the terms of the agreement, ADBSI may market PMS Escape product under a
different name and sublicense its rights, subject to Back Bay's written consent.
Upon the execution of this agreement, ADBSI agrees to pay a one-time,
non-refundable fee of $125,000 to Back Bay and to prepay for Back Bay's finished
PMS Escape and packaging inventory. The $125,000 fee was paid on ADBSI's behalf
by UTEK. The Company in turn, paid UTEK $25,000 to cover a portion of such fee.
In exchange for the license, ADBSI must pay BBS a royalty equal to 5% of the net
sales of PMS Escape and other products covered under the License Agreement.
Pursuant to the terms of the Acquisition Agreement, ADBSI will provide to Back
Bay a business plan that outlines the development and commercialization of the
PMS Escape product. Under this agreement, if ADBSI does not meet the annual
minimum royalty payments after the first year, Back Bay has the right to convert
the license to a non-exclusive license. ADBSI has the right, but not the
obligation, to prosecute any actions concerning any claims of infringement. The
term of this agreement is five years, with automatic three-year renewal terms so
long as royalty payments have been paid to Back Bay pursuant to the agreement.
ADBSI has the right to terminate the Patent License Agreement for Back Bay's
uncured breach of the license or by providing prior written notice to Back Bay
at least six months prior to either the expiration of the term on March 31, 2010
or each three-year renewal term. Back Bay may terminate the agreement for
ADBSI's uncured breach of the agreement or upon prior written notice in the
event the license becomes non-exclusive or if ADBSI ceases to conduct its
business related to this agreement.
ADBSI also entered into a Consulting Agreement with Back Bay and its
principals Marc Tobin, Judith Wurtman, Ph.D. and Dr. Richard Wurtman on March
31, 2005. Pursuant to the terms of the Consulting Agreement, Mr. Tobin, Dr.
Judith Wurtman and Dr. Richard Wurtman will provide consulting services relating
to PMS Escape and other products to which ADBSI obtains rights under the Patent
License Agreement. The initial term of the Consulting Agreement expires on April
1, 2009 and automatically renews for additional one-year terms, unless the
Patent License Agreement is no longer in effect or either party elects not to
renew the Consulting Agreement at least 30 days prior to the expiration of the
initial or renewal term. Upon the execution of the Consulting Agreement, gave
Back Bay a 10% equity ownership in ADBSI, which, in turn, converted into 10% of
the equity ownership UTEK received from the Company upon consummation of the
Acquisition Agreement. In consideration for the Consulting Agreement, ADBSI
agreed to pay Back Bay $200,000 in four equal payments of $50,000. The first
payment was made upon the effectiveness of the Consulting Agreement, and the
remaining three payments are due on the first, second and third anniversary
dates of the Consulting Agreement.

      The Acquisition Agreement and Press Release are filed herewith and are
incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(a) The Company will file financial statements of the business acquired, and any
required pro forma financial information, by an amendment to this Current
Report, which will be filed no later than the date required by Item 9.01 of Form
8-K.

(c) Exhibits.

Exh. No. Description
-------  -----------
10.1.    Agreement and Plan of Acquisition, dated March 31, 2005, by and
         between the Company, Anti-Depression BioHealth Solutions, Inc. and UTEK
         Corporation.

99.1     Press Release issued April 5, 2005.

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                               SWISS MEDICA, INC.
                                                  (Registrant)

Date: April 6, 2005
                                       /s/ Raghu Kilambi
                                       --------------------------------------
                                       Raghu Kilambi, Chief Executive Officer